Forsta AP Fonden Sells 6,700 Shares of The Clorox Company (NYSE:CLX)

Forsta AP Fonden decreased its stake in The Clorox Company (NYSE:CLX – Free Report) by 20.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,600 shares of the company’s stock after selling 6,700 shares during the period. Forsta AP Fonden’s holdings in Clorox were worth $4,209,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Kennon Green & Company LLC increased its holdings in shares of Clorox by 4.4% in the 1st quarter. Kennon Green & Company LLC now owns 1,558 shares of the company’s stock worth $247,000 after buying an additional 66 shares during the last quarter. GHP Investment Advisors Inc. boosted its stake in shares of Clorox by 1.3% in the 4th quarter. GHP Investment Advisors Inc. now owns 5,132 shares of the company’s stock valued at $720,000 after purchasing an additional 66 shares in the last quarter. Robinson Value Management Ltd. boosted its stake in shares of Clorox by 0.6% in the 4th quarter. Robinson Value Management Ltd. now owns 11,285 shares of the company’s stock valued at $1,584,000 after purchasing an additional 67 shares in the last quarter. M Holdings Securities Inc. boosted its stake in shares of Clorox by 0.9% in the 4th quarter. M Holdings Securities Inc. now owns 7,523 shares of the company’s stock valued at $1,056,000 after purchasing an additional 68 shares in the last quarter. Finally, Perigon Wealth Management LLC boosted its stake in shares of Clorox by 4.7% in the 3rd quarter. Perigon Wealth Management LLC now owns 1,617 shares of the company’s stock valued at $208,000 after purchasing an additional 72 shares in the last quarter. Institutional investors own 79.37% of the company’s stock.

Get Clorox alerts:

Clorox Stock Performance

Shares of NYSE CLX opened at $157.97 on Friday. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 14.40. The company has a market cap of $19.53 billion, a PE ratio of 272.37, a PEG ratio of 2.24 and a beta of 0.30. The firm’s 50-day moving average price is $161.25 and its 200-day moving average price is $154.86. The Clorox Company has a 52-week low of $124.58 and a 52-week high of $178.21.

Clorox (NYSE:CLX – Free Report) last posted its quarterly earnings data on Tuesday, May 2nd. The company reported $1.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.22 by $0.29. The company had revenue of $1.92 billion for the quarter, compared to the consensus estimate of $1.82 billion. Clorox had a net margin of 1.03% and a return on equity of 114.67%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.31 earnings per share. As a group, analysts anticipate that The Clorox Company will post 4.56 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada upped their price objective on shares of Clorox from $137.00 to $151.00 in a research note on Wednesday, May 3rd. UBS Group upped their price objective on shares of Clorox from $148.00 to $162.00 in a research note on Wednesday, May 3rd. Raymond James increased their price target on shares of Clorox from $165.00 to $185.00 in a research report on Wednesday, May 3rd. Bank of America increased their price target on shares of Clorox from $130.00 to $140.00 in a research report on Wednesday, May 3rd. Finally, StockNews.com began coverage on shares of Clorox in a research report on Thursday, May 18th. They set a “hold” rating for the company. Seven investment analysts have rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Clorox has a consensus rating of “Hold” and an average price target of $148.54.

Clorox Profile

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Further Reading

• Five stocks we like better than Clorox
• Pfizer Just Invested $25 million In This Biotech
• Cracks In The Labor Market? Not Yet, But They’re Coming 
• Levi’s: Buy On The Dip Or Downtrend In Play? 
• Who Wins And Who Loses With China’s Metal Restrictions
• 3 Large Semiconductor Makers Offering Dividends & Price Growth

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX – Free Report).

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.